Zavolosotine

Zavolosotine
Clinical data
Other names	CRN 04777, CRN-04777
Identifiers
	IUPAC name 4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide;
CAS Number	2604416-66-0;
PubChem CID	156065422;
IUPHAR/BPS	13224;
DrugBank	DB21531;
UNII	275EAX4XXX;
Chemical and physical data
Formula	C20H18F5N5O
Molar mass	439.390 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C(F)(F)F)NC(=O)C1=CN=C(C(=C1N2CC[C@@H](C2)N)C3=CC(=CC(=C3)F)F)C#N;
	InChI InChI=1S/C20H18F5N5O/c1-10(20(23,24)25)29-19(31)15-8-28-16(7-26)17(11-4-12(21)6-13(22)5-11)18(15)30-3-2-14(27)9-30/h4-6,8,10,14H,2-3,9,27H2,1H3,(H,29,31)/t10-,14-/m0/s1; Key:HQIIZMSUOLJYSO-HZMBPMFUSA-N;

Zavolosotine (CRN04777) is a chemical compound which acts as an agonist at somatostatin receptor 5. It inhibits insulin release and glucagon secretion, and has potential applications in the treatment of diabetes.^[1]^[2]

References

^ WO 2022/177988, Ferrara-Cook C, Krasner AS, "Somatostatin receptor type 5 agonist for the treatment of hyperinsulinism.", published 2022-08-25, assigned to Crinetics Pharmaceuticals Inc.
^ Ferrara-Cook C, Luo R, De La Torre E, Wang Y, Betz S, Madan A, et al. (November 2022). "PSUN304 CRN04777 an Oral, Nonpeptide SST5-selective Somatostatin Agonist Dose Dependently Suppresses Basal and Stimulated Insulin Secretion". Journal of the Endocrine Society. 6 (Suppl 1): A408–A409. doi:10.1210/jendso/bvac150.850. PMC 9624917.

[1] WO 2022/177988, Ferrara-Cook C, Krasner AS, "Somatostatin receptor type 5 agonist for the treatment of hyperinsulinism.", published 2022-08-25, assigned to Crinetics Pharmaceuticals Inc.

[2] Ferrara-Cook C, Luo R, De La Torre E, Wang Y, Betz S, Madan A, et al. (November 2022). "PSUN304 CRN04777 an Oral, Nonpeptide SST5-selective Somatostatin Agonist Dose Dependently Suppresses Basal and Stimulated Insulin Secretion". Journal of the Endocrine Society. 6 (Suppl 1): A408–A409. doi:10.1210/jendso/bvac150.850. PMC 9624917.

[1]

[2]